Clinical Trial Update: Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating dendritic cell vaccines in combination with dasatinib for metastatic melanoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• DASATINIB (Dasatinib)
• Dendritic Cell Vaccines

Snippet

Sponsor: Walter J. Storkus | Conditions: Metastatic Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2019-08-06